RACS commented that while some scientific evidence exists to indicate the potential therapeutic value of cannabis-derived products, there is also considerable evidence highlighting the dangers of frequent cannabis use. Overall the scientific and clinical evidence to justify legalisation is poor, and consequently RACS has formed the position not to support the pathway for patient access to medicinal cannabis in Australia or New Zealand.

Read RACS' complete submission and position paper in the link below.